Adenomyosis and IVF: Diagnosis, Impact & Treatment Strategies

Adenomyosis — a condition where endometrial-like tissue grows into the muscular wall of the uterus — has emerged as an increasingly recognized factor in IVF outcomes. Long considered primarily a cause of heavy, painful periods in women in their 30s and 40s, adenomyosis is now understood to affect implantation, increase miscarriage risk, and potentially reduce IVF success rates. The good news is that targeted treatment strategies before embryo transfer can significantly improve outcomes.

What Is Adenomyosis?

In adenomyosis, tissue similar to the endometrial lining is found within the myometrium (the muscular layer of the uterus). This displaced tissue responds to hormonal cycles just like the normal endometrium — it thickens, breaks down, and bleeds each month, but within the muscle wall rather than being shed through the cervix. Over time, this causes the uterus to enlarge, become tender, and develop areas of disrupted architecture that can affect fertility.

Adenomyosis exists on a spectrum from focal (small, localized areas) to diffuse (widespread throughout the myometrium). It frequently coexists with endometriosis — up to 70–80% of patients with adenomyosis also have endometriosis — though the two are distinct conditions.

Diagnosis

Adenomyosis was historically a pathological diagnosis — definitively identified only after hysterectomy by examining the removed uterus. In current fertility practice, diagnosis relies on imaging:

Transvaginal ultrasound (TVS): In experienced hands, TVS can identify adenomyosis with good sensitivity and specificity. Characteristic findings include an asymmetrically enlarged uterus, myometrial heterogeneity, poorly defined endometrial-myometrial border (the junctional zone), and small cystic spaces within the myometrium.

MRI: Magnetic resonance imaging is the most accurate non-invasive diagnostic tool. It clearly visualizes junctional zone thickening (the hallmark finding — a junctional zone exceeding 12mm is strongly suggestive) and can distinguish focal from diffuse adenomyosis. MRI is particularly useful when TVS findings are ambiguous.

Impact on IVF Outcomes

Research consistently shows that adenomyosis negatively affects IVF outcomes, though the magnitude varies by severity:

• Reduced implantation rates: The disrupted junctional zone impairs the normal contractions and molecular signaling involved in embryo implantation.
• Increased miscarriage rates: Studies report higher first-trimester loss in patients with adenomyosis, likely related to abnormal uterine contractility and compromised decidualization.
• Lower clinical pregnancy rates: Meta-analyses suggest a 25–30% relative reduction in clinical pregnancy rates per transfer in patients with adenomyosis compared to controls.
• Lower live birth rates: The cumulative effect of reduced implantation and increased miscarriage translates to lower live birth rates per cycle.

The severity of impact correlates with the extent of disease — diffuse adenomyosis with marked junctional zone disruption has a greater effect than focal, mild disease.

Treatment Strategies Before IVF

The primary medical strategy for adenomyosis before IVF is hormonal suppression to quiet the adenomyotic tissue and reduce uterine inflammation before embryo transfer:

GnRH agonist pre-treatment: A 2–3 month course of GnRH agonist (such as leuprolide/Lupron) before frozen embryo transfer is the best-studied approach. By creating a temporary menopausal state, GnRH agonists shrink the uterus, thin the adenomyotic tissue, reduce inflammation, and normalize the junctional zone. Multiple studies and meta-analyses support improved pregnancy rates with this approach.

Dienogest or oral contraceptives: Continuous progestin therapy or OCP use for 2–3 months before FET may provide similar suppressive effects, though with less robust evidence than GnRH agonists.

Anti-inflammatory protocols: Some clinics add doxycycline or other antibiotics to address the inflammatory component, particularly when chronic endometritis coexists.

Transfer Considerations

For patients with adenomyosis undergoing IVF, freeze-all with subsequent medicated FET after a suppression protocol is generally the recommended approach. Fresh transfer during a stimulated cycle is less ideal because the high estrogen levels of stimulation can activate adenomyotic tissue and worsen the inflammatory environment.

The typical protocol sequence is: stimulation and retrieval → embryo freezing → 2–3 months GnRH agonist suppression → medicated FET cycle with estrogen/progesterone priming → transfer.

This extended timeline is worth factoring into your planning — medical travelers should expect the treatment to span at least two trips (one for retrieval, one for transfer after the suppression protocol).

Treatment in Colombia

Colombian fertility specialists are experienced with adenomyosis management as part of IVF treatment planning. Clinics within JCI-accredited hospital systems in Medellín, Bogotá, and Cali have access to MRI for diagnosis, GnRH agonist medications for suppression protocols, and the laboratory infrastructure for freeze-all and FET approaches.

For medical travelers with known adenomyosis, the remote preparation phase — hormonal suppression at home before traveling for transfer — can be coordinated between your local gynecologist and the Colombian fertility team, minimizing time in-country while maximizing treatment effectiveness.

Colombia's healthcare system, ranked #22 globally by the WHO (2000 report), supports the multidisciplinary approach that adenomyosis patients benefit from — reproductive endocrinology, radiology, and gynecological surgery under one roof at major medical centers.

Explore Our Colombia Medical Network